Skin Cancer Clinical Trials
Melanoma
Learn More About Melanoma
For general information on melanoma (including risk factors, symptoms, diagnosis, and treatment) visit the Cancer Council’s website:
General Enquiries
For general questions about trial availability, eligibility, or the referral process, please contact us using the form below. Our team will respond as soon as possible.
| Protocol Number | Cancer Type | Study Name | Intervention | Mechanism of Action | Recruitment Status | Sponsor | Clinical.Trials.gov ID | Click to Enquire |
|---|---|---|---|---|---|---|---|---|
| CP-AU-007-01 | Melanoma | A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Immunotherapy | IL-2 and Inhibits IL-2Rα Binding in combo. | Open - Recruiting | Aulos Bioscience, Inc. | NCT05267626 | Enquire Now |
| PTT-4256-01 | Melanoma | A Modular, Open Label, Dose Finding, Phase 1/2 Clinical Trial in Patients With Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of PTT-4256. | Immunotherapy | Inhibitor of the pH-sensing G-protein-coupled receptor 65 | Open - Recruiting | Pathios Therapeutics Pty Ltd | NCT06634849 | Enquire Now |
| HMBD-001-103 | Melanoma | A Phase 1b Study to Evaluate HMBD-001 in Combination With Docetaxel With or Without Cetuximab in Participants With Advanced Squamous Non-Small Cell Lung Cancers, and HMBD-001 in Combination With Cetuximab in Participants With Advanced Squamous Cell Cancers | Targeted | Humanised IgG1 anti-HER3 monoclonal antibody | Open - Recruiting | Hummingbird Bioscience | NCT05910827 | Enquire Now |
| NST-628-001 | MELANOMA (CUTANEOUS/UVEAL) TRIALS | A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors (NST-628) | Targeted | MAPK pathway mutated/dependent advanced solid tumors - NRAS Q61 mutation only | Open - Recruiting | Nested Theraputics | NCT06326411 | Enquire Now |
| SR-8541A-001 | MELANOMA (CUTANEOUS/UVEAL) TRIALS | A Phase 1 open-label, dose-escalation, multi-center study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint inhibitor (ICI) in subjects with solid tumors. | Targeted | ENPP1 inhibitor | Open - Recruiting | Stingray Theraputics | NCT06063681 | Enquire Now |